RPG Life Sciences Limited (NSE:RPGLIFE)
India · Delayed Price · Currency is INR | Market Cap | 35.93B +3.9% |
| Revenue (ttm) | 7.08B +8.3% |
| Net Income | 1.15B -37.1% |
| EPS | 69.64 -37.1% |
| Shares Out | 16.54M |
| PE Ratio | 31.19 |
| Forward PE | n/a |
| Dividend | 24.00 (1.08%) |
| Ex-Dividend Date | Jun 27, 2025 |
| Volume | 3,358 |
| Open | 2,224.00 |
| Previous Close | 2,224.70 |
| Day's Range | 2,163.30 - 2,224.00 |
| 52-Week Range | 1,733.00 - 2,725.00 |
| Beta | -0.20 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 24, 2026 |
About RPG Life Sciences
RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmintics, anti-convulsant, anti-spasmodic, etc. It also provides generics for immunosuppressant therapy; and finished dosage formulations for various therapies, which include nephrology, rheumatology... [Read more]
Financial Performance
In fiscal year 2026, RPG Life Sciences's revenue was 7.08 billion, an increase of 8.28% compared to the previous year's 6.53 billion. Earnings were 1.15 billion, a decrease of -37.15%.
Financial StatementsNews
RPG Life Sciences Slides: Investor presentation
RPG Life Sciences has posted slides in relation to its latest quarterly earnings report, which was published on May 26, 2026.
RPG Life Sciences Transcript: Q4 25/26
Q4 FY26 saw 23.6% revenue growth and 48% EBITDA growth, with strong domestic and API recovery. Margin stabilization is expected as the API plant is fully operational, and new product launches and market expansion are set to drive future growth.
RPG Life Sciences Quarterly report: Q4 2026
RPG Life Sciences has published its Q4 2026 quarterly earnings report on April 30, 2026.
RPG Life Sciences Slides: Q4 2026
RPG Life Sciences has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on April 30, 2026.
RPG Life Sciences surges 11% to Rs 2,254 despite 74% profit fall — EBITDA growth and Rs 24 dividend tell the real story
RPG Life Sciences is up 11% on Wednesday, touching an intraday high of Rs 2,312.40, in what at first glance appears to be one of the more counterintuitive market reactions…
Why are RPG Life Sciences shares falling over 10% today? Explained
Shares of RPG Life Sciences fell sharply by over 10% in early morning trade today after the company reported a...
RPG Life Sciences Quarterly report: Q3 2026
RPG Life Sciences has published its Q3 2026 quarterly earnings report on January 27, 2026.
RPG Life Sciences Slides: Q3 2026
RPG Life Sciences has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on January 27, 2026.
RPG Life Sciences Transcript: Q2 25/26
Domestic formulations grew 17.2% YOY in Q2, outpacing the market, while API business is set to recover in H2 after a fire. EBITDA margin remains strong at 24%, and the company maintains a debt-free, cash-rich position, with continued expansion and digital initiatives.
RPG Life Sciences Quarterly report: Q2 2026
RPG Life Sciences has published its Q2 2026 quarterly earnings report on October 17, 2025.
RPG Life Sciences Slides: Q2 2026
RPG Life Sciences has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on October 17, 2025.
RPG Life Sciences drops nearly 6% following Q1 results
Shares of RPG Life Sciences Ltd fell 5.82% to ₹2,346.90 in early trade on Monday after the company posted a marginal decline in net profit for the quarter ended June 2025. The stock opened weak and qu...
RPG Life Sciences Quarterly report: Q1 2026
RPG Life Sciences has published its Q1 2026 quarterly earnings report on July 25, 2025.
RPG Life Sciences Slides: Q1 2026
RPG Life Sciences has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on July 25, 2025.
RPG Life Sciences shares surge nearly 8% after Q4 net profit jumps 786% on one-time land gain
Shares of RPG Life Sciences rose 7.64% to ₹2,277.60 on Monday, climbing ₹161.70 from the previous close of ₹2,115.90. The stock was among the top gainers on the NSE following the announcement of the c...
RPG Life Sciences surges 9.36% on robust Q3 FY25 earnings; net profit up 32% YoY
RPG Life Sciences Limited’s stock rallied 9.36% to ₹2,279.20 on the NSE as of 9:57 AM, driven by its strong Q3 FY25 results. The company reported a 31.99% year-on-year increase in net profit to ₹34.93...
Stocks in focus today, January 27, 2025: JK Cement, Balkrishna Industries, Shakti Pumps, Yes Bank, KEC International, Trident, RPG Life Sciences, Jubilant Pharmova
Several mid- and small-cap companies have released key updates today, focusing on their Q3 performance, acquisitions, and new business orders. JK Cement: Q3 sales volumes grew 5%, and the company anno...
RPG Life Sciences reports fire incident at manufacturing plant in Navi Mumbai
At present, the company is investigating the cause of the fire and assessing the extent of the damage caused. RPG Life Sciences reassured stakeholders that it has adequate insurance coverage for the a...